IMAX stock gains on box office momentum and analyst upgrades

IMAX (CA4525411025) stock is benefiting from a strong run at the box office and a series of analyst upgrades, with the shares recently quoted around 51.72 dollars on the New York Stock Exchange as of September 5, 2026 according to MarketBeat data. For retail investors, the combination of double digit revenue growth in the latest quarter and a healthy pipeline of large format releases keeps the growth story in focus.

Strong second quarter figures underpin sentiment

The latest reported figures give context to the current valuation. According to a recent overview by MarketBeat, IMAX delivered earnings per share of 0.43 dollars in its most recent quarter, released on July 23, 2026, beating the analyst consensus of 0.30 dollars by 0.13 dollars and marking a clear positive surprise for the market.

In the same quarter, IMAX generated revenue of 102.84 million dollars compared with consensus estimates of 96.09 million dollars, representing year over year growth of 12.2 percent versus the prior year period. The company also reported a return on equity of 15.47 percent and a net margin of 9.84 percent for that quarter, highlighting an improving profitability profile as premium large format screens capture a greater share of global box office receipts.

Analyst upgrades and price targets support IMAX stock

Analyst sentiment has turned increasingly constructive. A detailed analyst summary compiled by MarketBeat indicates that ten investment analysts currently rate IMAX as a Buy and three as a Hold, resulting in an average rating described as Moderate Buy. The same data set shows a consensus target price of 54.00 dollars per share, implying modest upside from the recent trading level and providing a reference point for investors monitoring the risk reward profile.

The analyst backdrop is reinforced by individual house actions. Research notes cited by MarketBeat mention that JPMorgan Chase and other firms have raised their price objectives on IMAX into the 50.00 to 54.00 dollar range following the July 24, 2026 earnings season, aligning with the broader view that the company can sustain mid teens earnings per share for the current fiscal year. As a group, analysts are forecasting full year earnings per share of around 1.49 dollars for IMAX, based on current estimates for the 2026 fiscal year, which, if achieved, would extend the recent profitability trend.

Box office momentum and installation activity

Beyond headline earnings, operating metrics show why IMAX features prominently in discussions about the recovery of cinema attendance. A recent summer box office recap cited by YourValley notes that IMAX achieved its best month ever in July 2026, with 257 million dollars in worldwide sales driven by demand for Christopher Nolan's The Odyssey, underscoring the appeal of premium formats for tentpole releases.

Earlier coverage of IMAX's second quarter performance reported that global IMAX box office reached 285 million dollars for that quarter, with markets outside China driving roughly 24 percent growth in international box office takings. In addition, the company achieved its highest quarterly theatre installations in a decade, adding new premium large format screens to its network and deepening its presence in key growth territories.

Representative product: IMAX theatrical experience

At the product level, the core offering remains the IMAX theatrical experience, combining proprietary projection systems, sound technology and specially formatted content to create immersive screenings in multiplexes and flagship cinemas worldwide. This premium format typically commands higher ticket prices than standard screenings and is often reserved for large scale blockbusters, which in turn helps lift average revenue per patron for cinema operators and supports IMAX's royalty and revenue sharing model.

IMAX stock and market data snapshot

From a market perspective, the latest available quote snapshot compiled by MarketBeat shows IMAX trading at 51.72 dollars as of the most recent session on September 5, 2026. The same data puts the company's market capitalization at around 2.84 billion dollars, with a price to earnings ratio of 71.83 based on trailing earnings and a beta of 0.40, indicating lower volatility than the broader market. For investors comparing valuation and growth, these figures sit against the backdrop of a 52 week trading range between 28.93 dollars and 55.57 dollars, with the current price closer to the upper end of that band.